Clinical Trial Update: Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial [Phase 1]

View source ↗

Summary

Phase I dose-escalation study of lobaplatin given concurrently with IMRT for nasopharyngeal carcinoma, evaluating safety and preliminary tumor responses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Lobaplatin (lobaplatin)

Snippet

Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University | Conditions: Acute Toxic Effects, Tumor Responses | Phase 1 | Status: COMPLETED